<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082966</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01812</org_study_id>
    <secondary_id>CALGB-50206</secondary_id>
    <secondary_id>CDR0000361745</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT00082966</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of bortezomib in treating patients who have&#xD;
      relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by&#xD;
      blocking the enzymes necessary for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the efficacy of bortezomib in patients with relapsed or refractory Hodgkin's&#xD;
      lymphoma using overall response rate as the primary efficacy endpoint.&#xD;
&#xD;
      II. To assess time to progression and 2-year overall survival after bortezomib therapy.&#xD;
&#xD;
      III. To evaluate the safety and tolerability of bortezomib in patients with&#xD;
      relapsed/refractory Hodgkin's lymphoma.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats&#xD;
      every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Adult Lymphocyte Depletion Hodgkin Lymphoma</condition>
  <condition>Adult Mixed Cellularity Hodgkin Lymphoma</condition>
  <condition>Adult Nodular Sclerosis Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-N-allylamino-17-demethoxygeldanamycin/bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed classical Hodgkin's lymphoma&#xD;
&#xD;
               -  No bone marrow biopsies or fine needle aspirates as the sole means of diagnosis&#xD;
&#xD;
               -  Core biopsies allowed if they contain adequate tissue for primary diagnosis&#xD;
&#xD;
          -  The following subtypes are allowed:&#xD;
&#xD;
               -  Nodular sclerosis&#xD;
&#xD;
               -  Lymphocyte rich&#xD;
&#xD;
               -  Mixed cellularity&#xD;
&#xD;
               -  Lymphocyte depletion&#xD;
&#xD;
               -  Classical Hodgkin's lymphoma, not otherwise specified&#xD;
&#xD;
          -  No nodular lymphocyte-predominant Hodgkin's lymphoma&#xD;
&#xD;
          -  Relapsed or refractory disease after at least 1 prior standard systemic cytotoxic&#xD;
             chemotherapy regimen&#xD;
&#xD;
          -  Measurable disease by physical exam or imaging studies&#xD;
&#xD;
               -  Any tumor mass &gt; 1 cm is allowed&#xD;
&#xD;
               -  No non-measurable disease only, including the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Bone marrow&#xD;
&#xD;
          -  No curative option available with high-dose therapy and stem cell transplantation&#xD;
&#xD;
          -  Performance status - 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 750/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
          -  No sensory or motor peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 3 months after&#xD;
             study participation&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior stem cell transplantation allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent dexamethasone or other steroidal antiemetics&#xD;
&#xD;
               -  Concurrent steroids for adrenal failure allowed&#xD;
&#xD;
          -  Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for&#xD;
             diabetes) allowed&#xD;
&#xD;
          -  Prior radiotherapy to a symptomatic lesion or one that may produce disability (e.g.,&#xD;
             unstable femur) is allowed provided other measurable disease is present&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  Recovered from all prior treatment&#xD;
&#xD;
          -  No prior bortezomib or other proteosome inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Bartlett</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

